GSK plc today announced that AREXVY™, an approved Respiratory Syncytial Virus (RSV) vaccine, is now available at major retail pharmacies in the U.S.
AREXVY is currently indicated for preventing RSV-lower respiratory tract disease in individuals 60 years and older. An estimated 76.5 million people aged 60 and older in the U.S. may benefit from this RSV vaccine.
RSV is a seasonal disease, and an outbreak was recently in Florida
RSV Vaccine Now Available at Pharmacies
South Africa's Measles Outbreak Continues
Over the past year, the Republic of South Africa has been confronted with a significant measles outbreak. Even with an aggressive vaccination program, new measles cases continue to be reported.
As of August 16, 2023, the National Institute for Communicable Diseases (NICD) has tested 6,616 serum samples for measles since epidemiological week 40, 2022, of which 1124 (17%) were confirmed positive.
Recently, the percentage of samples testing positive decreased to 9% in week #31.
Pandemic Tied to Greater Weight Gain in Youths 10 to 12 Years Old
Effects of the pandemic on weight gain were most pronounced in low-income youth